Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

被引:6
|
作者
Zhang, Qiongwen [1 ,2 ]
He, Ping [3 ]
Tian, Tinglun [3 ]
Yan, Xi [3 ]
Huang, Juan [4 ]
Zhang, Zhang [5 ]
Zheng, Hong [3 ,6 ]
Zhong, Xiaorong [3 ,6 ]
Luo, Ting [3 ,6 ]
机构
[1] Sichuan Univ, Canc Ctr, West China Hosp, Dept Radiat Oncol,Dept Head & Neck Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Breast Dis Ctr, Canc Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Innovat Ctr Biotherapy, Multi Lab Breast Dis,State Key Lab Biotherapy,Natl, Chengdu, Peoples R China
关键词
HER2-positive breast cancer; real-world studies; brain metastase; pyrotinib; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITOR; BRAIN METASTASES; CHEMOTHERAPY; TRASTUZUMAB; CISPLATIN;
D O I
10.3389/fphar.2023.1100556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metastatic breast cancer, have been rarely reported. Here, we evaluated the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive metastatic breast cancer (MBC).Methods: This was a prospective, real-world, observational cohort study. Through the Breast Cancer Information Management System, HER-2 positive MBC patients treated with pyrotinib between 2017/06 and 2020/09 were included. Provider-reported objective response rate, progression-free survival (PFS), and overall survival (OS) were considered in the assessment of treatment outcomes. Tumor responses to pyrotinib treatment were calculated using RECIST 1.1. Adverse events were evaluated using clinical records.Results: The trial involved 113 individuals who were receiving pyrotinib treatment, with an average age of 51 years. Complete response, partial response and stable disease were observed in 9 (8.0%), 66 (58.4%), and 17 (15.0%) patients, respectively, while progressive disease was recorded in 20 (17.7%) patients. After a median follow-up of 17.2 months, the median PFS was 14.1. The most common adverse events of any grade were diarrhea (87.6%), vomiting (31.9%), and palmar-plantar erythrodysesthesia (26.6%). Among the patients with brain metastases, the median PFS and OS were 15.2 and 19.8 months, respectively. In addition, pyrotinib has similar efficacy in various subtypes of HER2-positive MBC patients, as shown by the lack of a significant difference of PFS and OS among pyrotinib-treated patients with or without brain metastases, or patients using pyrotinib as first-line, second-line, third-line or beyond therapies.Conclusion: Our real-world results demonstrated equivalent clinical efficacy in HER-2 positive MBC patients compared to phase II and phase III clinical trials with pyrotinib, and promising outcomes in patients with brain metastases.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
    Luo, T.
    Zhang, Q.
    He, P.
    Zhong, X.
    Yan, X.
    Tian, T.
    Huang, J.
    Zhang, Z.
    Zheng, H.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S490 - S490
  • [2] Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study
    Yin, Sha
    Chi, Yajing
    Du, Yangyang
    Wang, Jingfen
    Shan, Changping
    Yi, Weiwei
    Shang, Mao
    Man, Xiaochu
    Tan, Qiaorui
    Li, Huihui
    [J]. CANCER MEDICINE, 2023, 12 (03): : 2333 - 2344
  • [3] Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study
    Li, Chao
    Bian, Xiaoli
    Liu, Zhaoyun
    Wang, Xinzhao
    Song, Xiang
    Zhao, Wei
    Liu, Yansong
    Yu, Zhiyong
    [J]. CANCER MEDICINE, 2021, 10 (23): : 8352 - 8364
  • [4] Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
    Zhang, Lili
    Wu, Xiaohong
    Zhou, Jun
    Zhu, Mingzhen
    Yu, Hao
    Zhang, Yusong
    Zhao, Yutian
    Han, Zhengxiang
    Guo, Yujiang
    Guan, Xiaoqing
    Wang, Xufen
    Xu, Hong
    Sun, Li
    Zhang, Jiaxin
    Zhuang, Min
    Xie, Li
    Yu, Shiyou
    Chen, Ping
    Feng, Jifeng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
    Li, Fu
    Liang, Yimin
    Luo, Ming
    Shen, Jiayue
    Zhou, Taosheng
    Liang, Yajing
    Tang, Xiaoqi
    Yuan, Huiming
    Zeng, Jian
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
    Gui, Xinyu
    Li, Huiping
    Yan, Ying
    Zhang, Ruyan
    [J]. ONCOLOGY LETTERS, 2020, 20 (06)
  • [7] Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
    Sun, Ying
    Chen, Beibei
    Li, Jisheng
    Peng, Ling
    Li, Shuguang
    Yu, Xuejun
    Li, Li
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7165 - 7174
  • [8] Real-world survival of Danish patients with HER2-positive metastatic breast cancer
    Artzi, Daniel
    Berg, Tobias
    Celik, Alan
    Kumler, Iben
    Kenholm, Julia
    Al-Rawi, Sami
    Jensen, Maj-Britt
    Andersson, Michael
    Knoop, Ann
    [J]. ACTA ONCOLOGICA, 2023, 62 (06) : 601 - 607
  • [9] Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
    Hao, L.
    Chen, J.
    Chen, M.
    Han, X.
    Pan, Y.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S489 - S489
  • [10] Pyrotinib in HER2-Positive local advanced or metastatic breast cancer patients: Results from a retrospective study in real-world setting
    Wang, Q.
    Chen, C.
    Wang, Y.
    Sun, S.
    Cheng, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S58 - S58